Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


12>>>
45 Items
Title  Creator  Group name  Publishing year 
Efficacy of a physiotherapy, yoga and patient education programme for patients with breast cancer and hormone therapy-induced pain: a multicentre randomised study protocol (SKYPE 2) Faravel et al. EquipeCTCS 2024-01-08
ATR inhibition potentiates FOLFIRINOX cytotoxic effect in models of pancreatic ductal adenocarcinoma by remodelling the tumour microenvironment Bruciamacchie et al. EquipeCG 2024-11-29
A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer Desroys du Roure et al. EquipePM 2024-01-30
Trismus Occurrence and Link With Radiotherapy Doses in Head and Neck Cancer Patients Treated With Chemoradiotherapy Faravel et al. EquipeAD 2023
Response to Somay et al. Letter to the Editor Regarding "Trismus Occurrence and Link With Radiotherapy Doses in Head and Neck Cancer Patients Treated With Chemoradiotherapy" Faravel et al. EquipeAD 2023
Improving the response to oxaliplatin by targeting chemotherapy-induced CLDN1 in resistant metastatic colorectal cancer cells Cherradi et al. EquipeMY 2023-04-11
Hypnosis on patients treated with adjuvant chemotherapy for breast cancer: A feasibility study Fabbro et al. EquipePC 2023-01
Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide Therapy Garcia-Prada et al. EquipeCTCS 2023-10-19
Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer Rabia et al. EquipeJC 2023
Anti-cathepsin D immunotherapy triggers both innate and adaptive anti-tumour immunity in breast cancer David et al. EquipePM 2023-11-29
A straightforward method to quantify circulating mRNAs as biomarkers of colorectal cancer Grosgeorges et al. EquipeMY 2023-02-15
A prospective registry study of stereotactic magnetic resonance guided radiotherapy (MRgRT) for primary liver tumors Bordeau et al. EquipeMY 2023-09-20
The desmoplastic growth pattern is associated with second-stage completion and longer survival in 2-stage hepatectomy for colorectal cancer liver metastases Khellaf et al. EquipeMY 2022-09-08
Targeting the splicing isoforms of spleen tyrosine kinase affects the viability of colorectal cancer cells Denis et al. PlateformePP2I 2022
Tailored Management with Highly-Selective Diversion for Low Colorectal Anastomosis: Biochemical Postoperative Follow-Up and Long-Term Results from a Single-Institution Cohort Rouanet et al. EquipeCTCS 2022-04
Sexual quality of life assessment in young women with breast cancer during adjuvant endocrine therapy and patient-reported supportive measures Bobrie et al. EquipePC 2022-04
Determination of biomarkers associated with neoadjuvant treatment response focusing on colibactin-producing Escherichia coli in patients with mid or low rectal cancer: a prospective clinical study protocol (MICARE) Taoum et al. EquipeCTCS 2022-12-02
Prospective evaluation of sexual health in breast cancer women during the first year of adjuvant hormonal treatment using a cancer patient's dedicated questionnaire: A glaring gap of communication between health professionals and patients Aptecar et al. EquipeCTCS 2021-04
Importance of Patient Education for At-home Yoga Practice in Women With Hormonal Therapy-induced Pain During Adjuvant Breast Cancer Treatment: A Feasibility Study Faravel et al. EquipeCTCS 2021 Jan-Dec
Evaluation of the environmental contamination and exposure risk in medical/non-medical staff after oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy Larroque et al. EquipePM 2021-08-21
Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models Rabia et al. EquipeCG 2021 Jan-Dec
Anti-Müllerian hormone concentration regulates activin receptor-like kinase-2/3 expression levels with opposing effects on ovarian cancer cell survival Chauvin et al. EquipeCG 2021-07
Anti-Müllerian hormone (AMH) autocrine signaling promotes survival and proliferation of ovarian cancer cells Chauvin et al. EquipeCTCS 2021-01-26
The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest Pichard et al. EquipeNB May 2020
Higher Anti-Tumor Efficacy of the Dual HER3-EGFR Antibody MEHD7945a Combined with Ionizing Irradiation in Cervical Cancer Cells Bourillon et al. EquipeAP Jan 17, 2020
12>>>
45 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés